| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/16/2004 | WO2004078102A2 Sterilization of beclomethasone drug particles for pulmonary delivery |
| 09/16/2004 | WO2004078092A2 Cream dispenser |
| 09/16/2004 | WO2004069228A3 Sustained release formulations of venlafaxine |
| 09/16/2004 | WO2004066980A3 Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| 09/16/2004 | WO2004066979A3 Sustained release device and method for ocular delivery of adrenergic agents |
| 09/16/2004 | WO2004058152A3 An extended release pharmaceutical composition of phenytoin sodium |
| 09/16/2004 | WO2004054637A3 Contrast media formulations having improved biological tolerance |
| 09/16/2004 | WO2004050028A3 Density-controlled particulate suspensions for foodstuff, cosmetic, pharmaceutical and other uses |
| 09/16/2004 | WO2004047794A3 An allergen dosage form |
| 09/16/2004 | WO2004045494A3 Biological glue based on thrombin-conjugated nanoparticles |
| 09/16/2004 | WO2004043389B1 Methods of treating cancer and related methods |
| 09/16/2004 | WO2004037203A3 Sustained release l-arginine formulations and methods of manufacture and use |
| 09/16/2004 | WO2004035109A3 Apparatus and methods for activating a delivery device |
| 09/16/2004 | WO2004035005A3 Three layer tear formulation |
| 09/16/2004 | WO2004026362A3 Dri nasal sprays |
| 09/16/2004 | WO2004012655A3 Anti-microbial compositions and methods of using same |
| 09/16/2004 | WO2003090682A3 Treatment and prevention of pulmonary conditions |
| 09/16/2004 | WO2003066063A8 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist |
| 09/16/2004 | WO2003031593A9 MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES |
| 09/16/2004 | WO2003000192A3 Renewable, carbohydrate based co2-philes |
| 09/16/2004 | WO2002064093A8 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| 09/16/2004 | WO2002050097A3 Anti-allergic complex molecules |
| 09/16/2004 | US20040181277 Irradiated stent coating |
| 09/16/2004 | US20040181116 Permanent magnet keeper-shield assembly |
| 09/16/2004 | US20040181034 Multimeric Apo A-I agonist compounds |
| 09/16/2004 | US20040180965 Benzydamine hydrochloride, polyoxyalkylene block copolymer, propylene glycol, in water having a pH value in the range of about 3.5 to 7 |
| 09/16/2004 | US20040180962 Dosage forms having prolonged active ingredient release |
| 09/16/2004 | US20040180961 poorly water-soluble aceclofenac, a polymeric base selected from the group consisting of polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, glycerolmonostearate, carbamer and poloxamer, and a surfactant |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180915 Methadone-containing compositions for parenteral administration and method of use thereof |
| 09/16/2004 | US20040180900 Therapeutic composition for repairing chondropathy |
| 09/16/2004 | US20040180870 Containing propylene glycol and 2-propanol or ethanol; clear, long shelf life; nonirritating, freezing resistance; low cost ear drops |
| 09/16/2004 | US20040180867 Daily administration of 17 beta-estradiol and every other day including norgestimate |
| 09/16/2004 | US20040180856 Aqueous solution including partially methylated cyclodextrin |
| 09/16/2004 | US20040180853 Allantoin-containing skin cream |
| 09/16/2004 | US20040180840 Blood brain barrier crossing and/or oral drug delivery; central nervous system tumors and cancer; such as etoposide attached to ethylene glycol oligomer or polymer; blood solubility, in vivo hydrolysis |
| 09/16/2004 | US20040180834 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 09/16/2004 | US20040180832 Sustained peptide-release formulation |
| 09/16/2004 | US20040180828 Apoptosis suppression; polypeptides of sequence 2 having surface groove including amino acid residues P325, G326, H343 and L344 |
| 09/16/2004 | US20040180827 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 09/16/2004 | US20040180386 Using major histocompatibility complex polypeptides as tools in identifying lymphocyte binding sites; immunosuppression and tumor therapeutics |
| 09/16/2004 | US20040180203 Nanomaterial compositions with distinctive shape and morphology |
| 09/16/2004 | US20040180147 Direct micro-patterning of lipid bilayers using UV light and selected uses thereof |
| 09/16/2004 | US20040180097 For encapsulating an unstable drug and/or a drug with unpleasant taste, drug entrapped in pores of grains |
| 09/16/2004 | US20040180096 Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
| 09/16/2004 | US20040180095 Biodegradable microspheres are administered by stereotactic injection directly into the tumor, into the peritumoral area or at the same time into the tumor and the peritumoral area |
| 09/16/2004 | US20040180094 Contacting a cell membrane with an encapsulation vesicle and a pore forming agent on the surface of the encapsulation vesicle; activation |
| 09/16/2004 | US20040180093 Polymer compositions with bioactive agent, medical articles, and methods |
| 09/16/2004 | US20040180092 For therapy of respiratory or inflammatory complaints in mammals |
| 09/16/2004 | US20040180091 Carbonated hydroxyapatite-based microspherical composites for biomedical uses |
| 09/16/2004 | US20040180089 Multilayer dosage forms containing NSAIDs and triptans |
| 09/16/2004 | US20040180088 Controlled release core is capable of swelling rapidly to at least about two times its original volume, and maintaining its physical integrity in gastrointestinal fluids for prolonged periods |
| 09/16/2004 | US20040180087 Include a buffering agent to stabilize and maintain the pH below 9, oral dosage |
| 09/16/2004 | US20040180086 Delivers the drug in a controlled release fashion to the upper small intestine |
| 09/16/2004 | US20040180085 Quickly disintegrating solid preparations |
| 09/16/2004 | US20040180083 Can be filled with a solution having a high water activity, for filling which is selected from the group consisting of medicaments, quasi drugs, cosmetics, health foods, foods, beverages, seasonings, perfumes and bath agents; stability, palatability and texture |
| 09/16/2004 | US20040180082 Dispersing triterpenoid in a polyol while heating; adding a base into the dispersion; dissolving phospholipid in ethanol and adding to dispersion; adding water to prepare emulsion; adding an acid to the emulsion to prepare submicron-liposome |
| 09/16/2004 | US20040180081 Compositions and kits for the removal of irritating compounds from bodily surfaces |
| 09/16/2004 | US20040180080 Fentanyl compound-containing edible patch to be applied to oral mucosa |
| 09/16/2004 | US20040180078 Extruded foodstuffs having maintenance level actives |
| 09/16/2004 | US20040180077 Unobtrusive, portable edible strip or film that can be administered inconspicuously without the requirement of a liquid to aid in administration |
| 09/16/2004 | US20040180075 Ocular therapeutic agent delivery devices and methods for making and using such devices |
| 09/16/2004 | US20040180074 Bioerodable polymeric adhesives for tissue repair |
| 09/16/2004 | US20040180066 Useful for threapy of pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV) |
| 09/16/2004 | US20040180062 Administering by whole-body spray, an effective amount of a vaccine comprising a live avirulent derivative of an enteropathogenic bacteria to the bird |
| 09/16/2004 | US20040180059 For alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject |
| 09/16/2004 | US20040180055 Anthrax bio-terrorism: therapeutic technology with "zero" time tolerance |
| 09/16/2004 | US20040180016 Diluent, alkanoic acid and polyethylene glycol monostearate |
| 09/16/2004 | US20040180007 Pharmaceutical chewing gum formulations |
| 09/16/2004 | US20040180006 Methods and compositions for blocking the calcium cascade |
| 09/16/2004 | US20040180005 of nanodispersions especially for the application of pharmaceuticals in humans and animals and a method for the in-situ formulation of a pharmaceutical dispersion. The invention relates in particular to a method for the production of phospholipid adducts |
| 09/16/2004 | US20040178530 High volume manufacturing of nanoparticles and nano-dispersed particles at low cost |
| 09/16/2004 | US20040178529 Process for the production of micro and/or nano particles |
| 09/16/2004 | US20040178523 Molded waveguides |
| 09/16/2004 | US20040177809 Electrostatic coating |
| 09/16/2004 | DE20023538U1 Controlled release, oral, HMG-Coenzyme (Co) A reductase inhibitor composition for once daily dosing in the reduction of serum cholesterol levels comprises an alkyl ester of hydroxy-substituted naphthalenes and a controlled release carrier |
| 09/16/2004 | DE10309064A1 Polymere Zusammensetzung auf Basis von PVA A polymeric composition based on PVA |
| 09/16/2004 | DE10297018T5 Depotmikrokügelchen für die Injektion von Huperzin-A-Verbindungen Depot microspheres for injection of Huperzine A compounds |
| 09/16/2004 | DE10250944B9 Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase Using a stylus for the application of nursing or agents in the nose |
| 09/16/2004 | CA2547939A1 Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof |
| 09/16/2004 | CA2533010A1 Enhanced delivery of sphingolipids |
| 09/16/2004 | CA2518442A1 Control release formulation containing a hydrophobic material as the sustained release agent |
| 09/16/2004 | CA2518148A1 Long acting injectable insulin composition and methods of making and using thereof |
| 09/16/2004 | CA2518143A1 Delivery system for drug and cell therapy |
| 09/16/2004 | CA2518136A1 Oral insulin composition and methods of making and using thereof |
| 09/16/2004 | CA2517745A1 Cataplasm base and cataplasm using the same |
| 09/16/2004 | CA2517352A1 Liposome composition for reduction of liposome-induced complement activation |
| 09/16/2004 | CA2516629A1 Compositions and methods for preventing and treating endotoxin-related diseases and conditions |
| 09/16/2004 | CA2516098A1 Oxytocin controlled release formulations and methods of using same |
| 09/16/2004 | CA2515098A1 Invisible patch for active agent controlled delivery |
| 09/16/2004 | CA2514733A1 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| 09/15/2004 | EP1457431A2 Injection moulded water-soluble container |
| 09/15/2004 | EP1457256A1 Adsorbent for phosphoric acid |
| 09/15/2004 | EP1457212A1 Eye drops |
| 09/15/2004 | EP1457208A1 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 09/15/2004 | EP1457207A1 Solid compositions containng compounds unstable to oxygen and method for stabilization thereof |
| 09/15/2004 | EP1457204A1 Release control type formed product |
| 09/15/2004 | EP1457203A1 Solid, exactly dosable pharmaceutical forms for single release from dosing devices and related methods |
| 09/15/2004 | EP1457202A2 Topical formulation comprising a NSAID, preferably diclofenac, for alleviating pain/inflammation caused by herpes virus infection |
| 09/15/2004 | EP1456459A2 Undergarments containing active substances |